SCHEMBL5226740

SCHEMBL5226740

O=C(Nc1ccccc1F)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 2/20 0.67
ALDH1A1 P00352 2/20 0.61
HTT P42858 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
MAPT P10636 1/20 0.60
RORC P51449 1/20 0.60
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
CYP1A2 P05177 2/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
CTSD P07339 1/20 0.58
POLB P06746 1/20 0.57
GAA P10253 1/20 0.57
NCOA1 Q15788 1/20 0.57
NCOA3 Q9Y6Q9 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7157788 0.89 CRHBP (0.67) KCNMA1HTTSMN1; SMN2MAPTRORC
SCHEMBL394289 0.87 KCNMA1 (0.79) KCNMA1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL5666222 0.85 P2RX1 (0.57) KCNMA1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL9646962 0.84 KCNMA1 (0.64) KCNMA1ALDH1A1SMN1; SMN2RORCMEN1
SCHEMBL4958325 0.83 KCNMA1 (0.64) KCNMA1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL4958316 0.83 KCNMA1 (0.64) KCNMA1ALDH1A1HTTSMN1; SMN2MEN1
SCHEMBL28069367 0.83 KCNMA1 (0.78) KCNMA1ALDH1A1HTTSMN1; SMN2RORC
SCHEMBL7722700 0.83 ALDH1A1 (0.68) KCNMA1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL7717663 0.82 ALDH1A1 (0.66) KCNMA1ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL1963164 0.82 KMT2A (0.65) KCNMA1ALDH1A1HTTRORCMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3046563-B1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS CALITOR SCIENCES LLC (US) 2019-05-29 EP disclosed
CN-104513235-B Substituted amino-metadiazine compound and its application method and purposes 广东东阳光药业有限公司 2017-12-05 CN disclosed
US-9670194-B2 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC (US) 2017-06-06 US disclosed
US-9518046-B2 Substituted aminopyrimidine compounds and methods of use CALITOR SCIENCES, LLC (US) 2016-12-13 US disclosed
US-20160318913-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-11-03 US disclosed
EP-3046563-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Calitor Sciences, LLC (US) 2016-07-27 EP disclosed
CN-104513235-A Substituted aminopyrimidine compound and use thereof GUANGDONG HEC PHARMACEUTICAL 2015-04-15 CN disclosed
WO-2015042077-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-03-26 WO disclosed
US-20150087663-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-03-26 US disclosed
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087663-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MYD88 KCNMA1 4379/4885ALDH1A1 2295/4885HTT 3782/4885
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 KCNMA1 1122/4885ALDH1A1 835/4885HTT 3857/4885
US-20160318913-A1 SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, MYD88 KCNMA1 4422/4885ALDH1A1 2302/4885HTT 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.